# A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)

> **NCT04737330** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Thyroid Eye Disease
- Graves Orbitopathy

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04737330
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-29
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Analysis of blinded patient data showed a very low probability of the study meeting the primary efficacy endpoints. No safety concerns were identified
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04737330

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04737330, "A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04737330. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*